Plain-English translation of NCT04915508 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
The EXCALIBUR trial is testing a newer form of radiation therapy called stereotactic body radiotherapy (SBRT) for men whose prostate cancer has come back after having their prostate surgically removed. Instead of spreading treatment over many weeks, this approach delivers focused radiation in just 1–2 weeks. The trial is comparing how this faster treatment affects side effects and quality of life compared to traditional longer radiation schedules.
After prostate surgery, some men develop rising PSA levels or find cancer cells remain in the area where the prostate was. Standard radiation therapy to treat this takes 8–9 weeks and can cause lasting bowel and bladder problems. This trial exists to see whether the newer, faster radiation approach works just as well while causing fewer or less severe side effects.
You will receive radiation therapy every other day or on consecutive days for up to 2 weeks, delivered by a specialized machine that focuses high-dose radiation on the prostate bed and nearby lymph nodes. Your doctor may also give you during or after radiation, depending on your specific situation. After treatment ends, you will have follow-up visits every 3 months for the first year, then every 6 months, during which doctors will check your PSA levels and ask about any side effects or symptoms you're experiencing.
AI-generated summary from trial data · Jul 19, 2026 · Not medical advice
United States